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Combined Quantification of the Global
Proteome, Phosphoproteome, and Proteolytic
Cleavage to Characterize Altered Platelet
Functions in the Human Scott Syndrome*□S
Fiorella A. Solari‡§§, Nadine J.A. Mattheij§§§, Julia M. Burkhart‡, Frauke Swieringa§,
Peter W. Collins¶, Judith M.E.M. Cosemans§, Albert Sickmann‡!**,
Johan W.M. Heemskerk§‡‡, and Rene´ P. Zahedi‡‡‡
The Scott syndrome is a very rare and likely underdiag-
nosed bleeding disorder associated with mutations in the
gene encoding anoctamin-6. Platelets from Scott patients
are impaired in various Ca2!-dependent responses, in-
cluding phosphatidylserine exposure, integrin closure,
intracellular protein cleavage, and cytoskeleton-depen-
dent morphological changes. Given the central role of
anoctamin-6 in the platelet procoagulant response, we
used quantitative proteomics to understand the underly-
ing molecular mechanisms and the complex phenotypic
changes in Scott platelets compared with control plate-
lets. Therefore, we applied an iTRAQ-based multi-
pronged strategy to quantify changes in (1) the global
proteome, (2) the phosphoproteome, and (3) proteolytic
events between resting and stimulated Scott and control
platelets. Our data indicate a limited number of proteins
with decreased (70) or increased (64) expression in Scott
platelets, among those we confirmed the absence of
anoctamin-6 and the strong up-regulation of aquaporin-1
by parallel reaction monitoring. The quantification of 1566
phosphopeptides revealed major differences between
Scott and control platelets after stimulation with throm-
bin/convulxin or ionomycin. In Scott platelets, phosphor-
ylation levels of proteins regulating cytoskeletal or signal-
ing events were increased. Finally, we quantified 1596
N-terminal peptides in activated Scott and control plate-
lets, 180 of which we identified as calpain-regulated,
whereas a distinct set of 23 neo-N termini was caspase-
regulated. In Scott platelets, calpain-induced cleavage of
cytoskeleton-linked and signaling proteins was down-
regulated, in accordance with an increased phosphoryla-
tion state. Thus, multipronged proteomic profiling of
Scott platelets provides detailed insight into their pro-
tection against detrimental Ca2!-dependent changes
that are normally associated with phosphatidylserine
exposure. Molecular & Cellular Proteomics 15:
10.1074/mcp.M116.060368, 3154–3169, 2016.
The Scott syndrome is a very rare, moderately mild bleed-
ing disorder, clinically identified by a reduced prothrombin
consumption of the blood serum. Platelets and other blood
cells from Scott patients show a deficiency in Ca2!-depen-
dent membrane phospholipid scrambling (1, 2). As a result,
Scott platelets are greatly impaired in externalization of the
aminophospholipids, phosphatidylserine (PS)1, and phos-
phatidylethanolamine in response to strong, Ca2!-mobilizing
agents like collagen/thrombin or ionomycin (3–6). This leads
to a severe reduction in the binding of several coagulation
factors in Scott syndrome platelets, which explains the bleed-
ing phenotype in these rare patients (7). So far, one family and
two independent patients with Scott syndrome have been
described in the literature. In addition, a breeding of dogs with
impaired hemostasis is known with the same platelet pheno-
type (8). On the other hand, the Scott syndrome as a moder-
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ately mild bleeding disorder likely is underdiagnosed, because
the indicative lab diagnostics (prothrombin consumption test
or PS exposure) are not regularly performed.
In 2010, a critical role was reported for the transmembrane
protein anoctamin-6 (gene ANO6, alias TMEM16F), in the
Ca2!-dependent PS exposure of platelets (9). A role of
anoctamin-6 in Scott syndrome was postulated by the dis-
covery of dysfunctional mutations in the ANO6 gene of two
unrelated patients (9, 10). This anoctamin is also known as a
Ca2!-dependent ion channel with permeability to both chlo-
ride ions and cations (10), which activity appeared to be
defective in Scott cells (5, 9). A dysfunctional mutation in
ANO6 (TMEM16F) has also been identified in a breeding of
dogs with impaired hemostasis (8).
Recent findings however question if a deficiency of
anoctamin-6 alone can account for the complex phenotype of
Scott syndrome platelets. The platelets from a patient with
ANO6 mutations and from anoctamin-6 deficient mice show a
complex phenotype: along with agonist-induced PS expo-
sure, closure of activated integrins appears to be affected, as
well as calpain-dependent cleavage of intracellular proteins
and cytoskeletal-dependent swelling of the platelets (6, 11,
12). Given this, we expected that extended proteomics anal-
ysis will provide important novel information on the possible
roles of other proteins than anoctamin-6 in the altered prop-
erties of Scott platelets.
For the present work, we hypothesized that the complex
phenotypical changes in Scott platelets are a consequence of
multiple alterations in the platelet signaling machinery, directly
or indirectly related to the absent anoctamin-6 expression,
and that these alterations may provide insights into the mech-
anisms underlying the important procoagulant response.
Thus, we compared platelets isolated from healthy controls
and a diagnosed Scott patient in terms of functional (proco-
agulant) activity in relation to changes in protein levels, phos-
phorylation patterns, and proteolytic cleavage. Control and
Scott platelets were therefore activated with (1) thrombin, (2)
convulxin/thrombin, and (3) ionomycin, representing different
levels of procoagulant activity. Given major differences in
protein expression levels between human and mouse plate-
lets, we confined this work to the human system.
For the complex proteome analysis, we applied iTRAQ sta-
ble isotope labeling in conjunction with TiO2 phosphopeptide
enrichment and high pH reversed phase fractionation, allow-
ing simultaneous quantitative analysis of the global proteome
and phosphoproteome of (activated) Scott and control plate-
lets (figure 1). Such mass spectrometry-based techniques
have previously been used for a separate quantification of the
majority of proteins (13, 14) and regulated protein phosphor-
ylation sites in platelets isolated from healthy subjects (15,
16). We also applied our recently developed charge-based
fractional diagonal chromatography (ChaFRADIC) approach
to identify neo-N-terminal peptides, produced upon proteo-
lytic activity (17–20). This allowed us to distinguish between
calpain- and caspase-mediated protein cleavage patterns in
Scott and control platelets. To our knowledge, this is the first
time that such a broad combination of proteomics technolo-
gies has been used to assess the (post-translational) protein
changes in a human blood cell, here platelets, isolated from,
to our knowledge, the only available Scott patient worldwide.
EXPERIMENTAL PROCEDURES
Materials
Convulxin was purified to homogeneity from crude snake venom
(21). Proteinase-activated receptor-1 (PAR-1) agonist peptide
SFLLRN was from Bachem (Bubendorf, Switzerland), human
!-thrombin and ionomycin were from Sigma-Aldrich (St. Louis, MO).
Fluorescein isothiocyanate (FITC)-labeled anti-CD62P mAb against P-
selectin was from Beckman Coulter (Marseille, France); FITC-an-
nexin A5 from PharmaTarget (Maastricht, The Netherlands); Alexa
Fluor (AF)647-labeled fibrinogen from Invitrogen Life Technologies
(Bleiswijk, The Netherlands); ABT-737 from Santa Cruz Biotechnology
(Santa Cruz, CA); QVD-Oph and calpeptin from Calbiochem (San
Diego, CA). Other chemicals, (ant)agonists and antibodies were ob-
tained from sources described before (11).
Patient and Control Subjects—Blood was obtained from four
healthy volunteers and a diagnosed patient with Scott syndrome
(ScottUK, the only one available worldwide for blood donations) after
full informed consent (Helsinki declaration). The ScottUK patient has
been characterized as heterozygous for two mutations in the ANO6
alleles: a transition at the first nucleotide of intron 6 (IVS6 ! 1G3A),
disrupting the splice site consensus sequence of intron 6, and a
single-nucleotide insertion in exon 11 (c.1219insT), predicting a
frameshift at codon 411 (10). Both mutations are not compatible with
normal translation. Not available to this study were the two other
described Scott patients (1, 2). However, mutations in ANO6 have
also been identified in these patients from the United States (9) and
France (F. Toti, personal communication). Protocols were approved
by the local Medical Ethics Committees.
Blood Collection and Platelet Isolation—Blood samples were col-
lected into 1/6 volume of acid-citrate glucose solution (ACD, 80 mM
trisodium citrate, 52 mM citric acid, and 180 mM glucose). Platelet-rich
plasma (PRP) was obtained by centrifuging at 260 " g for 15 min (11).
After addition of 1/15 volume of ACD, platelets were pelleted by
centrifugation at 870 " g for 15 min. To obtain highly purified plate-
lets, pellets were resuspended in Hepes buffer pH 6.6 (10 mM Hepes,
136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, and 0.1% glucose) by
carefully excluding the bottom layer of red blood cells. After addition
of ACD (1/15 volume) and apyrase (1 U/ml), the cells were centrifuged
again at 2000 " g for 5 min in an Eppendorf centrifuge, and resus-
pended in Hepes buffer pH 7.45 (10 mM Hepes, 136 mM NaCl, 2.7 mM
KCl, 2 mM MgCl2, 0.1% glucose), again by excluding the bottom layer
of erythrocytes. Purity of the final platelet suspensions was checked
with a Thrombocounter and from microscopic preparations. Contam-
ination with red blood cells was #1:15,000, contamination with leu-
kocytes was #1:20,000. Blood samples were used for measurements
of platelet phenotype and for platelet proteomic analysis in parallel.
Platelet Stimulation and Thrombus Formation—Purified, washed
platelets (controls and Scott patient) in Hepes buffer pH 7.45 (10 mM
Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.1% glucose)
containing 2 mM CaCl2 were left untreated or were activated with
thrombin, thrombin/convulxin, or ionomycin for 30 min at 37 °C under
nonstirring conditions. This time point was chosen, based on earlier
findings that 30 min of activation with agonists was required for near
maximal PS exposure and integrin closure/cleavage in control plate-
lets (11, 12).
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For obtaining reference values for apoptosis-induced caspase
protein substrates, platelets were treated for 1 h with the BH3 mimetic
ABT-737, an agent that is in study for the therapeutic targeting of the
Bcl-2 family of prosurvival proteins in antitumor treatment. This com-
pound provides a standard way to induce apoptotic PS exposure in
platelets (6, 22).
For proteomics (global, phospho, N termini) analysis, platelet sam-
ples (5.0 " 108/ml) were collected into 1 volume of lysis buffer (50 mM
Tris, 1% SDS, 150 mM NaCl, 1 tablet PhosStop/7 ml, pH 7.8) (15).
Lysed samples were immediately frozen and stored at $80 °C until
usage. Parallel samples (1.5 " 108/ml) were analyzed by flow cytom-
etry for PS exposure using FITC-labeled annexin A5, as described
before (6).
Collagen-induced thrombus formation was assayed using PPACK/
fragmin-anticoagulated human blood (controls and Scott patient), as
described (12). Blood samples were perfused over a collagen surface
at shear rate of 1000/s for 4 min. Thrombi formed were poststained
with AF647-annexin A5 and FITC-anti-CD62P mAb. Phase-contrast
and fluorescence images were recorded to determine platelet depo-
sition, P-selectin expression, and PS exposure (12).
Western Blot Analysis—Washed platelets (5 " 108/ml) were left
untreated or activated by convulxin (200 ng/ml) plus thrombin (8 nM)
or ionomycin (20 "M) in the presence of 2 mM CaCl2 for 30 min at
37 °C under nonstirring conditions. Samples of resting and activated
platelets were lysed with ice-cold 4" lysis buffer (600 mM NaCl, 10
mM Tris, 4 mM EGTA, 4 mM EDTA, 4% Nonidet P-40). Samples (10 "g
proteins) were separated on 8% SDS-PAGE gels, and transferred to
PVDF blotting membranes. Immunoblotting was with the following
antibodies: Ab762 against the full length #3-chain (1:10000), Ab754
against the intracellular amino acid 754 neo-N terminus of the
cleaved #3-chain (1:1000), or !-tubulin (1:1000) (12). Incubation
with secondary horse radish peroxidase-coupled antibody (1:1000)
was overnight at 4 °C. Blots stained with an ECL system were
quantified by densitometric analysis.
Sample Digestion and Preparation for Quantitative (Phospho)Pro-
teomics—Platelet proteomics analyses were performed, based on
procedures reported earlier (13, 15, 23), with modifications. Well
purified platelet samples (5 " 108 platelets) were prepared in SDS
lysis buffer, and protein concentrations were determined using a
bicinchoninic acid assay (Pierce, Thermo-Fisher Scientific, Bremen,
Germany). Cysteines were reduced by 30 min incubation at 56 °C
with 10 mM dithiothreitol; free sulfhydryl groups were alkylated with 30
mM iodoacetamide for 30 min at room temperature. Samples of 150
"g protein were then processed using filter-aided sample preparation
(FASP) with a 30 kDa molecular weight cut-off spin filter (24, 25).
Proteins were digested in 50 mM triethylammonium bicarbonate
(TEAB), 200 mM guanidinium hydrochloride, and 2 mM CaCl2, pH 8.0
in the presence of trypsin (1:20 w/w, T-1426, Sigma, St. Louis, MO) at
37 °C. After incubation for 7 h, digested peptides were collected by
centrifugation at 13,800 " g for 25 min. Filters were washed with 50
"l of 50 mM TEAB and 50 "l of LC-MS grade water to increase
peptide yield. Trypsin digestion was monitored by monolithic RP
HPLC as described (23). After lysis and digestion with trypsin, sam-
ples were used for either label-free proteome analysis, or iTRAQ-
based (phospho)proteome analysis.
iTRAQ Labeling and Pooling—The workflow for assessment of the
global platelet proteome and platelet phosphoproteome is schema-
tized in Figure 1. Samples were dried under vacuum and reconsti-
tuted in iTRAQ 8-plex dissolution buffer (AB Sciex, Dreieich, Ger-
many), followed by individual labeling with iTRAQ 8-plex labels (113,
114, 115, 116, 117, 118, 119, and 121) according to the manufactu-
rer’s protocol, and pooling. The pooled peptide sample was desalted
by C18 solid phase extraction (SPEC C18 AR, 4 mg bed; Agilent
Technologies, Brussels, Belgium), dried under vacuum, and %6%
was reconstituted into 10 mM ammonium acetate pH 6.0 (solvent A)
for high pH reversed phase (RP) fractionation and subsequent quan-
tification of the global proteome. The remaining %94% of the sample
was used for phoshopeptide enrichment (see below).
Platelet Global Proteome Analysis Using iTRAQ Labels—Fifty mi-
crograms of the iTRAQ-labeled pooled peptide sample were sepa-
rated by RP at pH 6.0. Therefore, the sample was loaded on a C18
column (BioBasic-18, 5 "m particle size; 300 Å pore size, 150 " 0.5
mm), using a binary gradient at flow rate of 12.5 "l/min ranging from
3–60% of 10 mM ammonium acetate and 84% acetonitrile, pH 6.0, in
70 min. A total of twenty concatenated fractions were collected, and
analyzed by nano LC-MS/MS in data-dependent acquisition (DDA)
mode, using a U3000 nano-RSLC system online-coupled to a Q-
Exactive mass spectrometer. Half of each fraction was loaded onto a
trap column (Acclaim PepMap100 C18; 100 "m " 2 cm) with 0.1%
trifluoroacetic acid (TFA). Peptides were separated on the main col-
umn (PepMap100 C18; 75 "m " 50 cm), using a binary gradient
ranging from 3–42% solvent B (84% acetonitrile, 0.1% formic acid) in
100 min at 60 °C and a flow rate of 270 nL/min. In the Q-Exactive,
survey scans were acquired at resolution of 70,000, using the polysi-
loxane m/z 371.1012 as lock mass (26), with an automatic gain control
target value of 3 " 106. Subsequently, MS/MS spectra of the 15 most
intense ions were acquired with (1) a resolution of 17,500, (2) an isolation
width of 2.0 m/z; (3) a normalized collision energy of 35; (4) an AGC
target value of 1 " 106 ions; (5) a maximum injection time of 250 ms; (6)
a dynamic exclusion of 12 s and an underfill ratio of 10%. The first fixed
mass was set to 105 m/z. Reaction tubes containing 10% ammonium
water were placed in front of the ion source, in order to compensate for
the iTRAQ-induced increase of peptide charge states (27).
Raw data were processed with Proteome Discoverer 1.4 (Thermo-
Fisher Scientific) using the Uniprot human database (August 2012;
20,232 target sequences). Mascot and Sequest were applied as
search algorithms with the following settings: (1) trypsin as enzyme
allowing two missed cleavages, (2) iTRAQ 8-plex at N termini and
lysine (!304.2053 Da) and carbamidomethylation of cysteine
(!57.0214 Da) residues as fixed modifications, (3) oxidation of me-
thionine (!15.9949 Da) as variable modification, (4) mass tolerances
for MS and MS/MS were set to 10 ppm and 0.02 Da, respectively.
False discovery rate (FDR) estimation on the level of peptide spectrum
matches (PSM) was performed using the peptide validator node with
filtering for 1% FDR (high confidence filter). The reporter ion quantifier
node was used for iTRAQ reporter quantification. Only proteins
quantified with at least two unique peptides were considered. Details
for the data analysis are given in the supplemental methods.
Label-free Analysis of Global Platelet Proteome—In addition we
conducted a label-free quantification workflow using the unstimulated
Scott and healthy platelet samples. An advantage of this strategy is
that it is not affected by potential co-isolation interference frequently
observed in reporter ion-based quantification methods (28, 29).
Therefore, 500 ng of untreated healthy and Scott platelets were
analyzed by nano-LC-MS/MS in DDA mode, using a U3000 nano-
RSLC system online-coupled to an Orbitrap Fusion mass spectrom-
eter, with LC parameters as above. Survey scans were acquired at a
resolution of 120,000, using the polysiloxane m/z 445.1200 as lock
mass (26), an automatic gain control target value of 4 " 105, and a
maximum injection time of 50 ms. The top 20 precursor ions were
selected for fragmentation by HCD with a collision energy of 27 and
MS/MS were acquired in the Orbitrap using a target value of 5 " 104
ions, a maximum injection time of 50 ms, and a dynamic exclusion of
30 s.
Data analysis for label-free quantification was performed using
Progenesis LC-MS software version 4.1 from Nonlinear Dynamics
(Newcastle upon Tyne, UK), in combination with PeptideShaker 1.9.2
(30). After alignment peak lists were exported and searched against a
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concatenated target/decoy version of the human Uniprot database
(December 2013; 20,274 target sequences), using X! TANDEM
Vengeance (version 2015.12.15.2), Mascot 2.4 (Matrix Science), MS-
GF! Beta (v10282) (12/19/2014), OMSSA and SearchGUI 2.8.1 (28).
The following search parameters were used: (1) trypsin as protease
with a maximum of two missed cleavages, (2) carbamidomethylation
of Cys (!57.0214 Da) as fixed, and (3) oxidation of Met (!15.9949 Da)
as variable modification. MS and MS/MS tolerances were set to 10
ppm and 0.02 Da. Search results were combined using Peptide-
Shaker 0.29.1, filtered at an FDR of 1% and reimported into Progen-
esis. Peptide sequences containing oxidized Met and pyro-Glu ob-
tained from the second pass X!Tandem search were omitted from
further data analysis, and only proteins quantified with at least two
unique peptides were considered for quantification. For all proteins,
ratios between platelet samples were calculated based on normalized
areas obtained from Progenesis. Next, after log 2 transformation
mean and standard deviations were calculated and regulation factors
were defined as described in the Experimental Design and Statistical
Rationale section (& 2 " S.D. (2 " 0.535)).
Platelet Phosphoproteome Analysis—For phosphopeptide analysis
of the pooled iTRAQ samples, a TiO2-based phosphopeptide enrich-
ment protocol was conducted, as reported by Larsen and co-workers
(31). Samples were dried under vacuum and resuspended in TiO2
loading buffer (80% acetonitrile, 5% TFA, and 1 M glycolic acid). TiO2
beads were added in a bead-to-peptide ratio of 6:1. The suspension
was incubated for 10 min at RT, and centrifuged to pellet the beads
containing the phosphopeptides. This step was repeated twice using
1/2 and 1/4 of the amount of beads. Beads were pooled and washed
with 80% acetonitrile, 1% TFA, followed by a second washing step
with 10% acetonitrile, 0.1% TFA. Phosphopeptides were eluted with
1% ammonium hydroxide, pH 11.3. The eluted phosphopeptides
were recovered and dried under vacuum, followed by a second
enrichment step using loading buffer 2 (70% acetonitrile, 2% TFA).
The eluates were acidified using TFA (pH #2) and desalted using
Oligo R3 microcolumns. Enriched phosphopeptides were fraction-
ated with a U3000 nano-RSLC system in hydrophilic interaction liquid
chromatography (HILIC) mode. Peptides were loaded on a self-
packed HILIC column (Polar phase TSKgel Amide-80; 150 "m ID "
15 cm length; 5 "m particle size; 80 Å pore size, Tosoh Bioscience,
Stuttgart, Germany), and separated using a binary gradient ranging
from 5–40% solvent B (solvent A: 98% acetonitrile, 0.1% TFA; sol-
vent B: 0.1% TFA) within 40 min at a flow rate of 4 "l/min. Eluting
peptides were collected in nine fractions.
All HILIC fractions were analyzed by nano-LC-MS/MS in DDA
mode using an U3000 nano system, online coupled to an Orbitrap
Velos mass spectrometer (Thermo-Fisher Scientific). Peptides were
preconcentrated on a self-packed precolumn (Kinetex; 2.6 "m parti-
cle size; 100 Å pore size) and further separated on a self-packed main
column (Kinetex, 75 "m ID " 30 cm length; 2.6 "m particle size; 100
Å pore size) using a binary gradient as above, however ranging from
3–45% B in 75 min at a flow rate of 250 nL/min and 60 °C. Survey
scans were acquired with a resolution of 30,000 using the polysilox-
ane m/z 371.1012 as lock mass (26). Subsequently, HCD MS/MS
spectra of the five most intense ions were acquired in the Orbitrap
with (1) a resolution of 7500 (2) an isolation width of 2.0 m/z; (3) a
normalized collision energy of 50; (4) an AGC target value of 1 " 105
ions; (5) a maximum injection time of 200 ms; (6) and a dynamic
exclusion of 12 s. Reaction tubes containing 10% ammonium water
were placed in front of the ion source (27).
Data Analysis for Quantitative Phosphoproteomics—Phosphopro-
teomic raw data were processed with Proteome Discoverer 1.3
(Thermo-Fisher Scientific), using Sequest and Mascot as search al-
gorithms and the same parameters as used for the global iTRAQ
proteome. Additionally, phosphorylation of Ser/Thr/Tyr (!79.9663 Da)
was selected as a variable modification and probabilities for phos-
phorylation site localizations were determined using phosphoRS (32).
PSMs were filtered for 1% FDR (high confidence filter), and only
phosphopeptides with phospho-RS probabilities $90% were consid-
ered as confident.
iTRAQ ratios obtained from Proteome Discoverer were processed
as described for the global iTRAQ data and normalized using the
iTRAQ global proteome normalization factors in order to compensate
for systematic errors (see supplemental Methods).
For determination of confident phosphorylation sites, a ready-to-
use Excel macro provided by Mechtler lab (http://ms.imp.ac.at) was
used. Peptides were grouped based on their sequences, protein
accessions, and phosphorylation sites. Next, for each PSM, normal-
ized abundance values were calculated as for the global proteome.
For grouped PSMs representing the same protein, phosphopeptide
sequence or phosphorylation site, average normalized abundance
values were calculated per iTRAQ channel. Ratios were then obtained
for unstimulated and stimulated platelets per protein and subject.
Then, the ratio cohorts were compared between subjects.
Targeted Protein Quantification by Parallel Reaction Monitoring
(PRM)—To validate differential proteins obtained from global quanti-
tative proteomics we used targeted PRM to quantify selected proteins
in unstimulated platelets from three healthy controls and the Scott
patient. Therefore, we used a U3000 nano-RSLC system online-
coupled to an Orbitrap Fusion mass spectrometer, with LC parame-
ters as above. The polysiloxane m/z 445.1200 was used for lock mass
calibration. Target peptides were isolated in the quadrupole with an
isolation window of 0.4 m/z and fragmented using HCD with a colli-
sion energy of 30. The AGC target value was set up to 1 " 105 ions,
the maximum injection time to 200. MS/MS spectra were acquired in
the Orbitrap with a resolution of 30,000. For data analysis we used
MS/MS spectra from the label-free quantification data (see above) as
well as in-house spectral libraries and Skyline (33).
Charge-based Fractional Diagonal Chromatography (ChaFRADIC)
for Determination of N-terminal Cleavage Sites—Scott and healthy
platelet lysates were diluted 10-fold with ice cold ethanol and stored
at $40 °C for 1 h. Afterward, samples were centrifuged at 18,000 "
g for 30 min at 4 °C. Protein pellets were resuspended into 10 "l 10%
SDS under ultrasonication, and diluted to 1% SDS with 0.5 M TEAB
containing 20% (v/v) isopropanol. After addition of iTRAQ 8-plex
reagents in isopropanol (40 "l), labeling was performed on the protein
level for 2 h at 25 °C, in order to block free protein N termini and Lys
residues. The eight samples were pooled, and reactions were
quenched by addition of 60 mM glycine (10 min), followed by 130 mM
hydroxylamine to reverse side reactions of hydroxyl groups (10 min).
For proteolytic digestion, the multiplexed sample was divided into
three aliquots of %160 "g protein, which were individually subjected
to ethanol precipitation as described above. Proteolytic digestion was
performed and controlled, as described above. Digestion was
stopped with 1% TFA. The peptide mixtures were desalted using C18
solid phase tips (SPEC C18 AR, 4 mg bed, Agilent Technologies).
ChaFRADIC was conducted as previously described (17). Dried pel-
lets were resuspended in 52 "l of SCX solvent A (10 mM KH2PO4 in
20% acetonitrile, pH 2.7). Peptide samples were separated at a flow
rate of 80 "l/min using a U3000 HPLC system with a polysulfoethyl A
column (150 " 1 mm; 5 "m particle size; 200 Å pore size; PolyLC),
and a tertiary buffer system, i.e. solvent A (see above), solvent B (10
mM KH2PO4, 250 mM KCl in 20% acetonitrile, pH 2.7), and solvent C
(10 mM KH2PO4, 600 mM NaCl in 20% acetonitrile, pH 2.7). The
following gradient steps were performed: 100% solvent A for 10 min;
followed by a linear ramp from 0–15% solvent B in 9 min; 9 min of
15% B; increase to 30% B over 8 min; 11 min at 30% B; increase to
100% B in 5 min. Five min later, solvent C was increased to 100% in
1 min; 5 min later, solvent A was increased to 100% in 1 min; and the
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column was equilibrated for 20 min. Five fractions were collected,
corresponding to charge states !1, !2, !3, !4 and '!4. These
were dried under vacuum and resuspended into 50 mM Na2HPO4 (pH
7.8). Free N termini of internal peptides, derived from trypsin diges-
tion, were blocked by trideutero (d3)-acetylation to reduce their
charge states at pH 2.7. Therefore, trideutero N-hydroxysuccinimide
acetate (d3-NHS acetate) was added to a final concentration of 20 mM
and, after 1 h at 37 °C, to 30 mM. After 2 h, the reaction was quenched
by treatment with 60 mM glycine (10 min), followed by 130 mM
hydroxylamine (10 min). Fractions were dried under vacuum and
desalted using Poros Oligo R3 reversed-phase material. Desalted
fractions were solubilized in 52 "l buffer A, and were individually
subjected to rechromatography using the same conditions as above.
Because of the acetylation between the first and second dimension
SCX fractionations, internal peptides shifted to earlier charge state
windows, whereas iTRAQ-labeled and endogenously acetylated N-
terminal peptides retained their charge state window and could be
enriched.
Fractions were desalted, resuspended in 15 "l of 0.1% (v/v) triflu-
oroacetic acid, and analyzed by nano-LC-MS/MS using a Q-Exactive
Plus online-coupled to a U3000 nano-RSLC system in DDA mode.
Survey scans were acquired at a resolution of 70,000, and the top 15
ions were selected for MS/MS at a resolution of 17,500. AGC values
were set to 1 " 106 for MS and 2 " 105 for MS/MS scans. A
normalized collision energy of 30 was used, and the first fixed mass
was set to 100 m/z. For the !3, !4, and !5 fractions, 10% ammonia
solution was placed in front of the ion source. For analysis of the !1
fraction, fragmentation of singly charged peptides was allowed, ex-
cluding m/z values of singly charged ions occurring in previous blank
runs. Generated raw data were searched against the human Uniprot
database (as above), using Proteome Discoverer version 1.4 and
Mascot as search engine, reporter ion quantifier and percolator
nodes. Enzyme specificities were set to semi-ArgC, as lysine resi-
dues were blocked by iTRAQ labeling on the protein level.
To separate peptides with N-terminal iTRAQ label from those with
endogenous N-acetylation, a two-step search strategy was per-
formed. First, data were searched with iTRAQ-8plex (!304.2053 Da)
as fixed modification at lysine and peptide N terminus. Second,
iTRAQ-8plex of lysine and acetylation of N termini (!42.0105 Da)
were set as fixed modifications. In both cases, carbamidomethylation
of cysteine (!57.0214 Da) was selected as fixed, whereas oxidation
of methionine (!15.9949 Da) was used as variable modification. Mass
tolerances were set to 10 ppm for MS and to 0.02 Da for MS/MS.
Identified peptides were filtered for high confidence corresponding to
an FDR #1% at the PSM level, and a search engine rank of 1. The
reporter ion quantifier node was adjusted according to the search
settings. Quantification of N-terminal peptides across samples and
conditions was performed as described for the phosphoproteome
analysis, including grouping, normalization, and rationing.
Identification of Calpain Substrates and Cleavage Sites—Hypothe-
sizing that calpain-induced cleavage in activated Scott platelets is
altered, we aimed to identify potential calpain substrates. Thus, for
the identification of calpain cleavage sites and substrates in control
and Scott platelets we pursued a two-step strategy.
First, to define a putative calpain consensus motif but not identify
substrates, we digested platelet lysates in vitro with calpain, at a
protein/enzyme ratio of 1:10 (w/w) using FASP to remove undigested
protein. Calpain treatment was performed in 50 mM Tris-HCl, 100 mM
NaCl, and 3 mM CaCl2 pH 7.45 (30 min at 30 °C). Vehicle controls
were run in the absence of calpain. Generation of proteolytic peptides
was confirmed by monolithic HPLC (23), showing an extensive pep-
tide pattern for the calpain-treated platelets, whereas the control
showed no peptide signals. Thus, the calpain samples were analyzed
by nano-LC-MS/MS, and data were processed as above, but with
enzyme specificity set to “none” to identify peptide sequences that
were generated upon calpain cleavage of denatured proteins. Icelogo
(http://iomics.ugent.be/icelogoserver/main.html) was used to visual-
ize potential consensus cleavage patterns considering four amino
acids N-terminal and C-terminal of cleavage sites, i.e. positions P4-
P4( according to Schechter and Berger (34).
Second, control platelets from healthy donor (1.5 " 108/ml) were
activated with ionomycin (10 "M) in the presence or absence of
calpain inhibitor, calpeptin (200 "M) for 30 min, or with the proapop-
totic agent, ABT-737 (10 "M) in the presence or absence of caspase
inhibitor QVD-OPh (20 "M) 60 min at 37 °C, and lysed as above.
These samples were used for N-terminal quantitative ChaFRADIC as
described above, in duplicate.
Deposition of Raw Data—Raw data and Proteome Discoverer
search results are deposited in the ProteomeXchange repository (34)
dataset identifiers PXD002883 and 10.6019/PXD002883.
Experimental Design and Statistical Rationale—
Sample Sets—Purified washed platelets from a healthy control
donor (5 " 108/ml) and Scott patient (5 " 108/ml), left untreated or
activated with thrombin, thrombin/convulxin or ionomycin were
used for (1) global label free quantification (only untreated condi-
tions), (2) combined iTRAQ global proteome and phosphoproteome
quantification (all samples), and (3) iTRAQ-based quantification of
N-terminal peptides. Owing to the limited amount of available sam-
ple, (1) and (2) were performed using one technical replicate, each.
Notably, the four different conditions in the global iTRAQ proteome
data plus the label free analysis can be considered as five technical
replicates. For (3) we conducted three technical replicates of the
entire workflow following protein labeling and precipitation as we
expected higher variations of the complex ChaFRADIC procedure
for which we only required 20 "g of protein per replicate and
condition (i.e. iTRAQ channel).
Furthermore, the same samples were used for Western blot and
flow cytometry (1.5 " 108/ml). Additionally, for flow cytometry exper-
iments platelets from two independent healthy control donors were
used. For whole blood flow experiments, blood from the only Scott
patient and from four healthy control donors was used.
For the identification of potential calpain substrates, platelets from
a healthy control donor (1.5 " 108/ml) were treated with ionomycin in
the presence or absence of calpain inhibitor, calpeptin for 30 min or
for 1 h with ABT-737, as well in presence or absence of calpain
inhibitor, calpeptin. These samples were used for quantitative N-ter-
minal peptide analysis with ChaFRADIC, using 2 technical replicates
as above.
For validation of differential proteins using PRM, platelets from
three healthy control donors (two from a completely different set of
samples) and platelets from the only Scott patient were used.
Analysis and Statistics—For the global proteome, interindividual
variation over all proteins was estimated by separate analysis of
samples (unstimulated platelets) from pairs of healthy subjects; after
log2 transformation this gave a mean S.D. of 0.158 (range 0.107–
0.200, n ) 4). Boundaries for relevant changes in patient samples
were set at 2 " S.D. (2 " 0.158) in comparison to median abundance
ratios, to determine up- or downregulation per protein. For interpre-
tation of iTRAQ phosphopeptide ratios, interindividual variation over
all phosphopeptides was estimated from separate analysis of resting
platelets from pairs of subjects; after log2 transformation, this gave a
mean S.D. of 0.385 (range 0.337–0.420, n ) 4). Boundaries for
relevant changes were again set at 2 " S.D. (2 " 0.385) in comparison
to median abundance ratios, for up- or downregulation per phospho-
peptide. For comparison of iTRAQ ratios of N-terminal peptides,
mean S.D. (log2 transformed) of four sample sets was 0.515; again
cut-off values for up- and downregulation were set at 2 " S.D. (2 "
0.515) in comparison to median abundance ratios.
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Data from functional tests were expressed as means & S.E. Sta-
tistical significance of differences between groups was determined
using a 2-way ANOVA. p values #0.05 considered significant. Lists of
ratios were compared by the Dunnett’s test for multiple groups.
RESULTS
Phenotypic Analysis of Scott Syndrome Platelets—To con-
firm the complex altered phenotype of Scott platelets, we
analyzed whole blood and isolated platelets from a Scott
syndrome patient with two likely disruptive mutations in the
anoctamin-6 alleles. In comparison to blood from healthy
control subjects, perfusion of the patient’s blood over colla-
gen resulted in normal formation of thrombi and normal P-
selectin expression (Fig. 2A, 2B), indicating that platelet in-
tegrin activation and !-granule secretion were unchanged.
However, with the patient’s blood PS exposure was greatly
reduced, leaving only small patches of exposed PS on some
platelets. Earlier, we have established that this near complete
failure of PS exposure is accompanied by an inability of the
platelets to swell and form a balloon-like morphology (35).
Similarly, isolated platelets from the Scott patient were greatly
impaired in PS exposure in response to strong Ca2!-mobiliz-
ing agonists, such as thrombin/convulxin (stimulating throm-
bin and collagen receptors) and to the Ca2!-ionophore iono-
mycin (Fig. 2C). With platelets from control subjects, PS
exposure with these agonists was high, i.e. in 41 & 5% and
94 & 1% of the platelets, respectively (means & S.E., n ) 3).
As reported before (6), thrombin alone induced only 7 & 2%
PS exposure in control platelets, whereas this fraction was
reduced to 2 & 1% in Scott platelets. Additional evidence for
decreased calpain activity in thrombin/convulxin-stimulated
Scott platelets came from Western blotting of platelet sam-
ples. Using an antibody recognizing the intact cytosolic N-ter-
minal site of the integrin #3-chain (Ab762) and an antibody
recognizing a calpain-cleaved N-terminal site in the #3-chain
FIG. 1. Strategy and workflow for combined determination of platelet quantitative (phospho)proteomics. Purified washed platelets (4 "
108) from a healthy donor and the Scott patient in CaCl2-containing medium remained resting or were stimulated with thrombin (8 nM),
thrombin/convulxin (200 ng/ml, 8 nM) or ionomycin (20 "M) for 30 min. After lysis and digestion with trypsin, all eight samples were individually
labeled with 8-plex iTRAQ reagent (113, 114, 115, 116, 117, 118, 119, and 121). For assessment of the quantitative proteome and the
phosphoproteome, the eight samples were pooled in a 1:1 ratio; 10% of the pooled sample was used for global proteome analysis and the
remaining 90% for phosphoproteome analysis.
FIG. 2. Phenotypic analysis of activated Scott platelets. A–B, Unchanged platelet deposition and P-selectin expression, but impaired PS
exposure in collagen-dependent thrombus formation. A, Thrombi formed by whole-blood perfusion from a control subject or Scott patient were
stained with FITC-anti-P-selectin mAb and AF647-annexin A5. Representative brightfield and fluorescence images (200 " 165 "m). B,
Surface-area-coverage of platelet deposition, P-selectin expression and PS exposure. C, Impaired PS exposure of Scott platelets stimulated
with Ca2!-elevating agonists. Washed platelets (1.5 " 108/ml) were activated with thrombin (4 nM), thrombin/convulxin (100 ng/ml, 4 nM), or
ionomycin (10 "M). Exposure of PS was determined after 30 min of activation. D, Reduced calpain-dependent integrin #3 cleavage of Scott
platelets. Washed platelets (5 " 108/ml) were preincubated with vehicle or one of the calpain inhibitors, calpeptin (200 "M), or MDL-28170 (200
"M), and then stimulated with thrombin/convulxin (100 ng/ml, 4 nM) for 30 min. Western blots were stained for intact integrin #3 with Ab762 or
for cleaved integrin #3 with Ab754. Blots were reprobed with anti-!-tubulin Ab as protein loading control. Lane 1, resting platelets; lanes 2–4,
thrombin/convulxin stimulated platelets: lane 2, vehicle treatment; lane 3 calpeptin treatment; lane 4, MDL-28170 treatment. Representative for
3 experiments. Means & S.E. (n ) 3–4), *p # 0.05 compared with controls (2-way ANOVA).
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(Ab754) (11), it appeared that Scott platelets showed a rela-
tively high staining with Ab762 and a weaker staining with
Ab754 (Fig. 2D). The Ab754 staining was completely antago-
nized with two calpain antagonists, calpeptin and MDL-
28170, thus demonstrating calpain-mediated protein cleav-
age of the integrin.
Quantitative Assessment of the Global Proteome of Scott
Platelets—To assess the platelet protein composition and
phosphorylation state, we compared well-purified washed
Scott and control platelets (contamination with erythrocytes
#1:15,000, with leukocytes #1:20,000). Freshly isolated
platelets stayed unstimulated or were stimulated with high
concentrations of thrombin, thrombin/convulxin, or ionomycin
for a prolonged time of 30 min, i.e. at conditions comparable
to those of the measurements of PS exposure. Samples were
lysed, digested with trypsin, and labeled with 8-plex iTRAQ
reagents for global and phospho-proteome analysis (Fig. 1),
whereas for N-terminal ChaFRADIC samples were iTRAQ la-
beled on the protein level, multiplexed and digested.
Using iTRAQ we quantified 2278 unique proteins with at
least two unique peptides (supplemental Data S1). This cor-
responded to %50% of the estimated platelet proteome (13).
Considering a minimum deviation of 2 " S.D. (log2 trans-
formed) for relevant changes 58 (2.5%) and 46 (2.0%) of
proteins were potentially down- or up-regulated in Scott
platelets, respectively (Fig. 3A). Owing to potential issue of
ratio compression in iTRAQ, we also performed label-free
proteome analysis (28, 29) of the unstimulated Scott and
control platelets. This label-free analysis resulted in the quan-
tification of 1435 unique proteins with at least two unique
peptides (supplemental Data S1). This data also pointed to a
high similarity of the protein distribution pattern in the Scott
and control platelets (Fig. 3B). Overall, the relative abundance
of individual proteins was comparable to earlier findings (13).
Importantly, the label-free analysis confirmed most changes
in abundance of the patient platelets obtained from iTRAQ
ratios (supplemental Table S1).
The protein with the strongest downregulation in Scott
platelets was anoctamin 6 (gene ANO6) (supplemental Table
S1). The proteins with the strongest decrease in Scott plate-
lets further include signaling and adapter proteins (genes
S100A8, S100A9) implicated in Ca2! regulation, and several
uncommon secretory proteins (genes PZP, MPO, AGT,
PON1). On the other hand, the most increased proteins in
Scott platelets (supplemental Table S1) surprisingly com-
prised the membrane channel protein aquaporin-1 (gene
AQP1). Most likely because of its apparent absence in control
platelets, aquaporin-1 could only be quantified in the iTRAQ
proteome with one regulated peptide, but it was highly up-
regulated in the label-free proteome with two peptides. The
list of up-regulated proteins also comprises proteins involved
in transcription and translation (RPLP2, RPLP0); and proteins
implicated in platelet activation (CD36, PRKAR2B) and PS
binding (ANXA5).
As independent validation of the ANO6 and AQP1 quanti-
fication, we also followed a more sensitive targeted approach.
Using parallel reaction monitoring (PRM) as a high resolution
MS/MS technique, we quantified peptides/proteins of interest
directly in whole platelet digests. Thus, in platelets from three
healthy controls and the Scott patient, we quantified six pep-
tides for ANO6, two peptides from AQP1 and, as indifferent
control proteins, $two peptides from hypoxia up-regulated
protein 1 (HYOU1) and LIM and SH3 domain protein 1
(LASP1). We selected aquaporin-1 as its up-regulation might
be compensatory for the anoctamin-6 ion channel deficiency,
which would be in agreement with the recently established
role of aquaporin water channels in platelet morphological
changes such as ballooning (35). For anoctamin-6, PRM in-
dicated that the residual signal in the Scott samples could be
attributed to noise, because of clear deviations in mass and
peak pattern (Fig. 4A). Hence, the abundance level of
anoctamin-6 in Scott platelets was below the detection limit,
i.e. at least 50–100 times lower than in control platelets (Fig.
4B). Aquaporin-1 could not be detected in any of the three
control samples, whereas it was clearly present in the Scott
patient platelets (Fig. 4C). As expected, abundance levels of
FIG. 3. Moderate changes in quantitative proteome of Scott
platelets. A, Ratios of iTRAQ-labeled fragments of 1961 unique pro-
teins were quantified in highly purified Scott and control platelets (no
stimulation). Ratios of Scott/control platelets were log2 transformed
and plotted as a function of the number of proteins. Ratios were
considered to be relevant if ' or # 2 " 0.158 from the median (log2
transformed). Of the 1961 proteins, 70 were assigned as downregu-
lated and 64 as up-regulated in Scott platelets. For pairs of controls
subjects (n ) 4), this yielded by default %45 proteins in either cate-
gory. B, Correlation of normalized area values of 1,435 unique pro-
teins from label-free global proteome analysis of Scott and control
platelets.
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the HYOU1 and LASP1 proteins were highly similar in all
platelet preparations. To confirm, that the increased aqua-
porin-1 levels in Scott platelets do not derive from potential
erythrocyte contaminations, we compared our proteomic data
with the erythrocyte proteome from Wis´niewski et al. (36) and
thus can exclude that the presence of aquaporin-1 in Scott
platelets may be explained by erythrocyte contamination. Al-
together, these data pointed to mostly moderate changes in
the global proteome of Scott platelets with exception of ANO6
and AQP1 proteins.
Changes in Phosphorylation Profile of Activated Scott
Platelets—After iTRAQ labeling and TiO2 enrichment of the
pooled Scott and control platelets, we quantified 1566 phos-
phopeptides, corresponding to 709 unique proteins (supple-
mental Data S2). Per identified phosphopeptide, again we
considered iTRAQ ratios as relevant changes, when deviant
outside the range of 2 " S.D. (log2 transformed) in distribution
curves from control platelets. Long-term (30 min) stimulation
of control or patient platelets with thrombin resulted in no
more than small changes in phosphorylation pattern (Fig. 5A).
This is in agreement with earlier work showing that protein
(tyrosine) phosphorylation in thrombin-stimulated platelets
peaks within 1 min (37), and is mostly returned to resting
levels after 10 min (38).
In contrast, platelet stimulation with thrombin/convulxin or
ionomycin dramatically increased the overall phosphorylation
state. Comparing ratio values of Scott to control platelets,
these agonists evoked an increased phosphorylation in 404
and 206 peptides, respectively (Fig. 5B). Conversely, the
same agonists evoked a decreased phosphorylation in 25 and
105 peptides, respectively. On the other hand, we assessed
that 90% of the phosphopeptides that were up-regulated in
activated control platelets were also increased in the patient’s
platelets (Fig. 5C). For the downregulated phosphopeptides,
lower percentages were obtained (Fig. 5D). Comparative anal-
ysis for the up-regulated phosphopeptides indicated a signif-
icant overall increase in the patient’s platelets after stimulation
with thrombin/convulxin or ionomycin (Fig. 5E) as compared
with the control. Also for the downregulated phosphopep-
tides, relative abundance levels in the Scott platelets were
significantly increased after thrombin/convulxin (Fig. 5F).
Jointly, these data pointed to an overall increased phosphor-
ylation state of the activated Scott platelets, especially after
stimulation with thrombin/convulxin.
Assignment tabling indicated that mostly Scott proteins of
the following functional classes were increased in phosphor-
ylation: cytoskeleton-linked; signaling and adapter proteins;
small GTPases and regulators; protein kinases and phospha-
tases; and membrane receptors and channels (Table I).
Zooming in to proteins with the strongest changes (supple-
mental Table S2) revealed decreased phosphorylation in
Scott platelets of several signaling and adaptor proteins
(genes PDE3A, ENSA, NCK2, STIM1), proteins implicated in
PS exposure (3, 39), i.e. BLC2 (BNIP2). The highest increases
in phosphorylation of Scott platelets were seen for several
cytoskeletal-linked proteins (SEP6, DBNL, PLEK, TNS1,
PDLIM7, MYH9, TNL1), and the small GTPase activator
ARHGAP6. These lists contain considerable overlap with the
FIG. 4. High-resolution parallel reaction monitoring
(PRM) for validation. A, Representative PRM analysis
of the anoctamin-6 peptide 167VLSVDESIIKPEQEFF-
TAPFEK188 in control and Scot platelets. Note that the
correct peptide at retention time of 31.0 min was pres-
ent in the control but not patient sample, whereas the
background peaks at 31.2 min show similar patterns
and intensities. Because of the mass deviation of $35.2
ppm and the incomplete peak pattern, the residual sig-
nal at 31.03 min in the Scott sample can be assigned to
noise. B, Normalized abundance of 6 peptides from
anoctamin-6, representing different parts of the protein,
in Scott platelets and platelets from three controls. Pep-
tides analyzed were 97QAYESNLICHGLQLEATR114,
167VLSVDESIIKPEQEFFTAPFEK188 (residual Scott sig-
nal can be attributed to noise, see above), 191MND-
FYIVDR199, 243AAFPLHDCK251, 335EVCHPDIGGK344,
and 649WEQDYHLQPMGK660. C, Normalized abun-
dance of peptides from anoctamin-6 (ANO6, 6 pep-
tides), aquaporin 1 (AQP1, 2 peptides), hypoxia up-
regulated protein 1 (HYOU1, 4 peptides), and LIM and
SH3 domain protein 1 (LASP1, 5 peptides). Intensities
for the patient sample were set to 1.0 and compared
with 3 control samples (except for ANO6).
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phosphoproteome changes reported for human platelets ac-
tivated with thrombin or oxidized phospholipids (16). To-
gether, these data suggested that the altered phosphorylation
pattern of Scott platelets upon strong stimulation involves
multiple cytoskeletal-linked proteins and modulators of PS
exposure.
Identification of Platelet Proteins Cleaved by Calpains or
Caspases—Platelet PS exposure is accompanied by activa-
tion of intracellular proteases, such as calpain isoforms in
platelets that are stimulated with strong Ca2!-elevating
agents (11) or with Ca2!-independent caspases in apoptotic
platelets (39). As Western blots indicated that calpain-medi-
ated integrin cleavage is impaired in Scott platelets, we set to
determine the substrates of this protease in platelets.
To identify calpain substrates in platelets we combined two
different approaches. First, as reports on calpain cleavage
specificity were controversial, we aimed at defining a consen-
sus motif. Therefore, we digested lysates from control plate-
lets in vitro with purified calpain to first obtain insights into the
general cleavage pattern, rather than to identify in vivo sub-
strates. The digested sample was analyzed by LC-MS, fol-
lowed by database searches without enzyme specificity. This
resulted in a list of 2224 unique peptides at 1% FDR corre-
sponding to 375 proteins. These peptides were used to de-
termine a cleavage pattern with IceLogo, identifying amino
acids overrepresented in the proximity of the cleavage site
(Fig. 6).
Second, we used our recently developed ChaFRADIC
workflow for determination of neo-N-terminal peptides
formed in vivo upon proteolytic cleavage (17, 18). Thus,
intact control platelets were stimulated with Ca2!-mobiliz-
ing ionomycin or the proapoptotic agent ABT-737 in the
presence or absence of calpain inhibitor calpeptin or
caspase inhibitor QVD-Oph (11). Quantitative analysis of the
platelet lysates by ChaFRADIC revealed 227 neo-N-terminal
peptides with a '3-fold increased levels in ionomycin-stimu-
lated platelets, 180 of which were inhibited by calpeptin, but
not by QVD-Oph (supplemental Table. S3A). These 180 cal-
peptin-sensitive neo-N-terminal peptides corresponded to
106 proteins. The in vivo list includes proteins previously
found to be cleaved in PS-exposing platelets, namely Src
kinase (SRC) and talin-1 (TLN1) (11). Interestingly, many
of the proteins seemed to be cleaved by calpain on multi-
ple sites, e.g. caldesmon (CALD1), a calpain-1 subunit
(CAPNS1), kindlin-3 (FERMT3), filamin-A (FLNA), myosin-9
(MYH9), talin-1 (TLN), vasodilator-stimulated phosphoprotein
FIG. 5. Phosphoproteomic changes
in Scott platelets subjected to strong
activation. iTRAQ-based quantification
of (un)stimulated control and Scott
platelets. Stimulation for 30 min was with
thrombin (Thr), thrombin/convulxin (Thr/
Cvx), or ionomycin (Iono). Abundance
ratios per identified phosphopeptide
were classified as changed when out-
side the range (log2 transformed) ' or #
2 " 0.385 compared with the median of
unstimulated cells (see Methods). 0, sta-
ble. A, Numbers of up- and downregu-
lated phosphopeptides in response to
agonists. B, Numbers of up- and down-
regulated phosphopeptides in (stimu-
lated) Scott platelets versus control
platelets. C, D, Numbers of up- and
downregulated phosphoproteins in con-
trol platelets with similar change in Scott
platelets. E, F, Box plots of Scott/control
ratios of all phosphopeptides, assessed
as up-regulated and downregulated in
ionomycin-stimulated control platelets,
per agonist condition. ***, Significant
with Dunnett’s test for multiple groups.
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(VASP), and zyxin (ZYX) that are cleaved at four or more
positions. The majority of the 106 proteins could be assigned
to the following functional classes: cytoskeleton-linked, mem-
brane and protein trafficking, or signaling and adapter pro-
teins (Fig. 7A).
In the apoptotic ABT-737-treated platelets, we identified 45
neo-N-terminal peptides with a '3-fold increase, 23 of which
were inhibited by QVD-Oph, but not calpeptin (supplemental
Table S3B). The corresponding 23 proteins, in part over-
lapped with the calpain-cleaved proteins—e.g. !-actinin-1
(ACTN1), FERMT3, glycoprotein Ib! (GPIBA), FLNA, leucine-
rich repeat flightless-interacting protein 1 (LRRFIP1), MYH9,
nexilin (NEXN), and Pyk2 (SKAP2)—but were caspase-
cleaved at a different position. The 23 identified caspase
substrates mostly categorized as cytoskeletal-linked or sig-
naling and adaptor proteins (Fig. 7B). Together, these results
revealed a pattern of distinct cleavage sites by calpains and
caspases in platelets, in particular of cytoskeletal-associated
and signaling proteins.
Changes in N-terminal Proteome of Activated Scott Plate-
lets—Next, we conducted quantitative N-terminal ChaFRADIC
to follow aberrant calpain activity in Scott platelets. Thus, also
platelets from the Scott patient and control subject were
analyzed by quantitative N-terminal ChaFRADIC. We quantified
1596 N-terminal peptides between Scott and control platelets
that were either unstimulated, or stimulated with thrombin,
thrombin/convulxin or ionomycin (supplemental Data S3). Con-
FIG. 6. Experimentally predicted calpain cleavage motif. LC-MS
analysis of an in vitro platelet digest identified 2224 high confident
calpain-generated peptides, corresponding to 375 unique proteins.
Icelogo representation of P4-P4( positions (4 amino acids upstream
to 4 amino acids downstream of the cleavage site) of the obtained
peptide data to visualize the experimentally obtained calpain cleav-
age consensus motif. Large size characters indicate amino acids
with a large positive or negative predictive contribution to calpain
cleavage.
TABLE I
Overview of differences in phosphoproteome of Scott platelets compared to healthy control platelets. 1566 quantified phosphosites corre-
sponding to 709 proteins were assigned to 21 platelet function classes. Numbers or percentages are shown per function class of phospho-
peptides with decreased or increased phosphorylation in activated Scott platelets in comparison to control platelets. Changes in abundance




Down Up Down Up Down Up
Cytoskeleton actin-myosin 2% 3% 35% 7% 20% 146
Cytoskeleton intermediate 33% 6
Cytoskeleton microtubule 1% 4% 3% 36% 7% 7% 73
Cytoskeleton receptor-linked 1% 5% 1% 26% 10% 13% 111
Endosomal proteins 29% 7
ER & Golgi proteins 8% 17% 8% 13% 24
Glucose metabolism 13% 13% 6% 6% 16
Lysosome & peroxisome proteins 67% 67% 3
Membrane & protein trafficking 3% 4% 2% 25% 5% 7% 102
Membrane receptors & channels 3% 3% 1% 22% 9% 13% 184
Mitochondrial proteins 38% 13% 13% 8
Other metabolism 4% 9% 11% 9% 15% 46
Other nuclear proteins 2% 26% 2% 7% 43
Phospholipid regulation 100% 100% 1
Proteasome 3% 5% 2% 14% 2% 9% 58
Protein kinases & phosphatases 1% 3% 3% 24% 6% 15% 151
Secretory proteins 5% 5% 11% 11% 19
Signalling & adapter proteins 5% 3% 2% 28% 6% 17% 259
Small GTPases & regulators 3% 4% 1% 29% 11% 12% 166
Transcription & translation 2% 5% 26% 14% 58
Unknown 3% 4% 1% 26% 5% 13% 80
Total 42 54 25 403 105 206 1564
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sidering again a deviation of 2 " S.D. (log2 transformed) in
distribution curves from control platelets as relevant changes,
we found that only thrombin/convulxin and ionomycin caused
major changes in abundance of N-terminal peptides, both in
control and Scott platelets (Fig. 8A). The same agonists also
induced major changes in the ratios of N termini in Scott
versus control platelets (Fig. 8B). In control platelets stimula-
tion induced up-regulation of 2 (thrombin), 223 (thrombin/
convulxin), and 318 (ionomycin) N-terminal peptides, respec-
tively, the majority of which was also increased in the Scott
platelets (Fig. 8C). Markedly, taken together all 318 up-regu-
lated N termini, the extent of up-regulation was significantly
decreased in thrombin/convulxin stimulated Scott platelets
(Fig. 8E). When reducing this list from 318 to 37 up-regulated
N-terminal peptides with confirmed cleavage by calpain, as
derived from our consensus sequence and inhibitor data, we
found that calpain cleavage-mediated up-regulation was sig-
nificantly reduced in Scott platelets after stimulation with
thrombin/convulxin, whereas it was more pronounced after
stimulation with ionomycin (Fig. 8F). Plotting of the altered
N-terminal peptides in Scott versus control platelets indicated
that more were decreased in the patient, such in contrast to
the higher numbers with increased phosphorylation of many
phosphopeptides (Fig. 9A–9B). Concerning the calpain-
cleaved N termini, thrombin/convulxin stimulation led to an
overall decrease, whereas ionomycin stimulation led to an
increase (Fig. 9C). Overall, these data pointed to a reduced
calpain activity in the Scott platelets when stimulated with
thrombin/convulxin, and an increased activity after ionomy-
cin stimulation. The latter difference was surprising, but can
be explained by the protection of Scott platelets to mem-
brane dysregulation during swelling and PS exposure at the
high intracellular Ca2! concentration reached with ionomy-
cin, which may prolong the calpain activity before the cells
die.
Interestingly, the top-15 of decreased N-terminal peptides
in the Scott patients (arranged according to ratios obtained
with thrombin/convulxin) showed in majority (1) a cleavage
pattern with two or more of our consensus amino acids
for calpain cleavage and (2) a complete inhibitory effect of
FIG. 7. Class distribution of calpain-
and caspase-cleaved proteins in
platelets. Control platelets were stimu-
lated with ionomycin (30 min) or ABT-
737 (60 min) in the presence or absence
of calpain inhibitor calpeptin or caspase
inhibitor QVD-OPh (see supplementary
Table S1). A, Distribution of 106 identi-
fied calpain-cleaved proteins over plate-
let function classes ('3-fold increased
cleavage with ionomycin and '50% re-
duction with calpeptin). B, Distribution of
23 identified caspase-cleaved proteins
over platelet function classes ('3-fold
increased cleavage with ABT-737 and
'50% reduction QVD-OPh).
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calpeptin, as established for control platelets (supplemental
Table S4A). This confirmed that these N-terminal peptides
were generated upon calpain cleavage. The top-15 of de-
creased neo-N-terminal peptides in the Scott patient includ-
ed cytoskeleton-linked proteins (genes DBLN, DNM1L,
MAPRE1, NEXN, SMIM1, TLN1, and ZYX) and key regulatory
signaling proteins (DOK3, FYB, GSK3B, PDE3A, VASP). In
contrast, the top-15 of increased N termini concerned a vari-
ety of proteins with cleavage sites which were not inhibited by
calpeptin (supplemental Table S4B). Hence, these cleavage
sites are unlikely to be calpain-mediated. Collectively, also
this analysis showed a decreased calpain-dependent forma-
tion of N termini in convulxin/thrombin-stimulated Scott plate-
lets. Interestingly, the majority of the identified calpain cleav-
age sites differ from those in previous lists of N termini in
human platelets (40), likely because these were obtained from
unstimulated, stored platelets rather than from activated
platelets, as in the present article.
DISCUSSION
Here we provide a first comprehensive quantitative analysis
of the protein composition, protein phosphorylation state and
protein cleavage pattern of isolated primary human cells, i.e.
well-purified blood platelets. By applying these sensitive pro-
teomics techniques to platelets of a patient with the congen-
ital Scott syndrome with mutations in the ANO6 gene, and a
complex altered phenotype (deficiency in Ca2!-dependent
swelling, PS exposure and protein cleavage), we could obtain
detailed insight into the changes in post-translational protein
modifications after stimulation of the platelets with strong
Ca2!-mobilizing agonists; and moreover, into the suspected
role of the Ca2!-dependent ion channel anoctamin-6 into
these changes. It is relevant to note that the observed phe-
notypic changes in patient blood samples, which were also
used for the proteomic analysis, correspond well to those
earlier described for platelets from Scott patients (3, 6, 11) as
FIG. 8. Changes in N-terminal pep-
tides in Scott platelets subjected to
strong activation. iTRAQ-based quanti-
tative N-terminal ChaFRADIC was used
to quantify changes in N-terminal pep-
tide abundance between (un)stimulated
control and Scott platelets, in order to
identify alterations in proteolytic activity.
Stimulation for 30 min was with thrombin
(Thr), thrombin/convulxin (Thr/Cvx), or
ionomycin (Iono). Abundance ratios per
identified peptide were classified as
changed when outside the range (log2
transformed) ' or # 2 " 0.504 com-
pared with the median of unstimulated
cells. A, Numbers of up- and downregu-
lated N-terminal peptides in response to
agonists. B, Numbers of up- and down-
regulated peptides in (stimulated) Scott
platelets versus control platelets. C, D,
Numbers of up- and downregulated N-
terminal peptides in control platelets
with similar change in Scott platelets. E,
Box plot of Scott/control ratios of all 318
N-terminal peptides assessed as up-
regulated in ionomycin-stimulated con-
trol platelets, per agonist condition. F,
Similar box plot, but for 37 confirmed
calpain-cleaved N-terminal peptides per
agonist condition. ***, Significant with
Dunnett’s test for multiple groups.
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well as for platelets from anoctamin-6 deficient mice (12).
Another note is that the availability of platelets of only one
Scott patient is a limitation of our study.
For all proteomics datasets, we systematically compared
the changes induced by strong Ca2!-mobilizing agonists
(thrombin/convulxin or ionomycin) and the differences be-
tween control and Scott platelets. Data were always com-
pared with platelet samples from different healthy donors, in
order to establish normal variability. For detecting differences
in protein abundance of post-translational modification, we
used relatively low threshold levels of 2 x S.D., taken from
normal distribution curves, in order not to lose relevant infor-
mation. On the other hand, to compensate for false-positive
results, we systematically used two or three ways of data
analysis to pinpoint the most consistent alterations in the
proteome of Scott platelets.
Analysis of the quantitative proteome indicated that
anoctamin-6 was essentially absent in Scott platelets,
whereas several other (Ca2! signaling) proteins were partly
reduced in abundance. These changes were confirmed by
PRM. Of interest is the appearance of the channel protein
aquaporin-1 in Scott but not in control platelets (3 individuals).
It is possible that the increased presence of aquaporin-1 is
compensatory for the anoctamin-6 ion channel deficiency.
This is in agreement with the recently established role of
aquaporin water channels in platelet morphological changes
such as ballooning (35). The link of the latter finding to the
Scott syndrome needs to be confirmed, but waits for diagno-
sis of new patients, given that the presently included patient is
the only one accessible for blood donations worldwide. Anal-
ysis of platelets from anoctamin-6 deficient mice might be an
alternative (12), but will raise questions because of the differ-
ent protein profile of mouse platelets in comparison to human
platelets, particularly regarding activation pathways.
Quantification of 1566 phosphopeptides revealed a high
similarity between Scott and control platelets after 30 min of
thrombin activation. After stimulation of either type of platelets
with thrombin/convulxin or ionomycin—both conditions that
induce prolonged Ca2! increases—we noted an overall in-
crease in up-regulated phosphorylation sites. The possible
explanation is calpain-mediated inactivation of prominent
Ca2!-dependent phosphatases in platelets. Furthermore,
FIG. 9. Altered protein phosphorylation and pro-
teolytic cleavage in activated Scott platelets. Sam-
ples of Scott and control platelets were left unstimu-
lated, or were stimulated for 30 min with thrombin (Thr),
thrombin/convulxin (Thr/Cvx) or ionomycin (Iono). Over-
view per agonist condition: A, changes in all 1566 phos-
phopeptides for (un)stimulated Scott platelets versus
control platelets; B, changes in all 1596 N-terminal
peptides for (un)stimulated Scott platelets versus con-
trol platelets; C, changes in 110 N-terminal peptides
identified as calpain-cleaved for (un)stimulated Scott
platelets.
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with these agonists we determined on average higher phos-
phorylation levels in the Scott platelets compared with control
platelets (see Table I). In particular, phosphorylation in the
patient platelets was increased in multiple proteins regulating
the cytoskeleton and implicated in phosphatidylserine expo-
sure. Detailed analysis indicated that the majority of phospho-
peptides up-regulated in stimulated control platelets was also
up-regulated in the patient platelets, yet at a higher extent.
Likely, this is a consequence of the longer viability of the Scott
platelets after stimulation with convulxin/thrombin or ionomy-
cin, as these cells do not swell and their membranes are less
dysfunctional as a consequence of anoctamin-6 induced
phospholipid scrambling. Whether aquaporin-1 can have a
(compensating) role in the altered signaling is unknown. As-
signment tabling indicated that mostly proteins were in-
creased in phosphorylation that were cytoskeleton-linked or
were involved in signaling (membrane receptors and channels;
protein kinases and phosphatases; signaling and adaptor pro-
teins; small GTPases and regulators). Interestingly, platelet
stimulation for 30 min stimulation with thrombin alone did not
result in significant phosphorylation changes, despite the fact
that this agonist evoked granule secretion and long-term integ-
rin activation. Accordingly, after long-term stimulation with
thrombin, the majority of protein phosphorylation changes must
have been re-equilibrated to the level at basal conditions.
ChaFRADIC analysis gave in total 1596 N-terminal peptides
in patient and control platelets, 180 of which were confirmed
to be calpain-regulated (corresponding to 106 proteins). We
further identified a distinct set of 23 N termini (23 proteins) as
caspase-regulated. Strikingly, in Scott platelets stimulated
with convulxin/thrombin, the calpain-produced N termini were
significantly downregulated, in particular from cytoskeleton-
linked and signaling proteins. This is in agreement with West-
ern blot analyses showing a reduced cleavage of Src kinase
and talin-1 in convulxin/thrombin stimulated Scott platelets
(11). It is tempting to relate the decreased protein cleavage to
the increased protein phosphorylation, but this is still un-
clear. On the other hand, ionomycin stimulation with pro-
longed high cytosolic Ca2! appeared to evoke more
calpain-mediated protein cleavage in Scott platelets, not
unlikely because of their prolonged survival allowing the
Ca2!-dependent calpain more time for proteolytic activity.
Taken together, our multipronged proteomic profiling has
provided novel insight into the altered protein composition
and post-translational protein machinery, which can explain
major Ca2!- and cytoskeleton-dependent membrane alter-
ations in Scott syndrome platelets.
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